KPV peptide research: what the mouse and cell studies measured
If you searched for “peptides for gut health”, this page covers what has been studied in that research area. KPV is a peptide people often ask about in connection with the gut. The studies in our register are in mice and in human cells in a dish. BPC-157 also has older human trials known only from conference abstracts.
- Evidence grade or review status for every compound
- Sources listed on every page
- US and sport status, dated
Compounds studied in this area
Grades describe the published evidence, not a promise of any effect.
What has been studied
In 2008, researchers gave KPV by mouth to mice with chemically induced colitis and also studied it in human intestinal epithelial and T-cell lines. These are mouse and cell results, not evidence of an effect in people. [1]
How far the research has gone
Pick a compound to see the highest rung reached, from cell study to approval.
What the research does not show
Saying what we don't know is part of the evidence.
Any effect of KPV in people: the studies in our register are mouse and cell studies.
Where it stands legally
As of November 2026. See the full tracker and the changelog.
| Compound | FDA approval | 503A compounding (2026) | WADA (2026 List) |
|---|---|---|---|
| KPV | Not approved | FDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yet | Not named; S0 covers unapproved substances |
| BPC-157 | Not approved | FDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yet | Prohibited (S0, named) |
Worth knowing
Research use only
None of the compounds on this page is an FDA-approved medicine. Nothing on this page is medical advice or describes use in people.
What research use only meansNo doses, ever
We publish no doses, protocols, or cycles for people, on any page.
Why we publish no dosesHow we grade evidence
Grades follow study design: cell and animal studies (preclinical), small human studies, then controlled human trials, with approval tracked separately. A grade is not a promise of any effect.
Evidence gradesQuestions people ask
Has KPV been tested in people?
Not in our register. The studies we hold are mouse and cell studies, so we make no statement about effects in people.
What does the October 2026 HHS policy say about KPV?
HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities, and licensed physicians compounding KPV under ten conditions, including a patient-specific prescription, while the list of permitted ingredients goes through rulemaking. The Federal Register notice calls the policy a draft; it is not binding and not an approval.
Sources
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. PMID 18061177. pubmed.ncbi.nlm.nih.gov/18061177/
- Klicek R, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats. J Pharmacol Sci. 2008;108(1):7–17. PMID 18818478. pubmed.ncbi.nlm.nih.gov/18818478/
- U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, 28 Oct 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting page, 23–24 July 2026: agenda, voting questions and FDA briefing (no minutes posted as of 17 November 2026). www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- World Anti-Doping Agency. Prohibited List 2026 (in force 1 January 2026) and 2027 (in force 1 January 2027). www.wada-ama.org/en/prohibited-list
- U.S. Department of Health and Human Services. Enforcement discretion policy, Appendix B: peptide identities and justifications, October 2026 (records the July 2026 committee outcome for each of the six peptides). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- Federal Register 91 FR 68526, 30 October 2026. Notice of availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (the notice calls the policy a draft). www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
- U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances (pp. 27, 40–43). www.fda.gov/media/193343/download
Start with the evidence
Every page sourced and dated, including what the research does not show.
Open the research library